US Stock MarketDetailed Quotes

Radiopharm Theranostics (RADX)

Watchlist
  • 4.390
  • +0.080+1.86%
Close Jun 11 16:00 ET
  • 4.390
  • 0.0000.00%
Post 20:01 ET
51.86MMarket Cap-1.18P/E (TTM)

Radiopharm Theranostics (RADX) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Jun 30, 2025
(FY)Jun 30, 2024
(FY)Jun 30, 2023
(FY)Jun 30, 2022
Total revenue
1,114.27%3.63M
2.35%299.23K
3,210.60%292.36K
8.83K
Operating revenue
1,114.27%3.63M
2.35%299.23K
3,210.60%292.36K
--8.83K
Cost of revenue
3.59M
0
0
Gross profit
-86.87%39.28K
2.35%299.23K
3,210.60%292.36K
8.83K
Operating expense
-7.45%34.68M
17.17%37.47M
60.52%31.98M
19.93M
Selling and administrative expenses
5.45%16.53M
2.68%15.67M
36.12%15.26M
--11.21M
-General and administrative expense
5.45%16.53M
2.68%15.67M
36.12%15.26M
--11.21M
Research and development costs
19.18%27.52M
2.01%23.09M
448.68%22.63M
--4.12M
Depreciation amortization depletion
-2.69%7.33K
14.97%7.53K
-99.78%6.55K
--2.98M
-Depreciation and amortization
-2.69%7.33K
14.97%7.53K
-99.78%6.55K
--2.98M
Other operating expenses
-624.80%-9.37M
78.16%-1.29M
-468.28%-5.92M
--1.61M
Operating profit
6.81%-34.64M
-17.30%-37.17M
-59.12%-31.69M
-19.92M
Net non-operating interest income expense
247.60%333.11K
-482.88%-225.69K
100.63%58.94K
-9.35M
Non-operating interest income
1,659.36%888.2K
-65.19%50.48K
--145.04K
----
Non-operating interest expense
-89.84%65.3K
646.75%642.89K
-99.08%86.09K
--9.35M
Total other finance cost
233.56%489.79K
---366.72K
----
----
Other net income (expense)
62.39%-3.93M
-255.37%-10.45M
-186.00%-2.94M
-1.03M
Gain on sale of security
45.47%138.14K
136.91%94.96K
74.99%-257.25K
---1.03M
Special income (charges)
61.42%-4.07M
-292.96%-10.55M
---2.68M
----
-Less:Restructuring and merger&acquisition
-54.07%4.07M
230.08%8.86M
--2.68M
----
-Less:Impairment of capital assets
----
-52.29%1.48M
--3.1M
----
-Gain on sale of property,plant,equipment
--0
---1.69M
--0
----
Other non- operating income (expenses)
----
-227.89%-7.57M
--5.92M
----
Income before tax
20.09%-38.24M
-38.41%-47.85M
-14.12%-34.57M
-30.29M
Income tax
7.19%103.29K
153.56%96.36K
-14.40%38.01K
44.4K
Net income
20.04%-38.34M
-38.54%-47.95M
-14.08%-34.61M
-30.34M
Net income continuous Operations
20.04%-38.34M
-38.54%-47.95M
-14.08%-34.61M
---30.34M
Minority interest income
Net income attributable to the parent company
20.04%-38.34M
-38.54%-47.95M
-14.08%-34.61M
-30.34M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
20.04%-38.34M
-38.54%-47.95M
-14.08%-34.61M
-30.34M
Basic earnings per share
85.82%-5.28
-9.63%-37.23
25.93%-33.96
-45.8515
Diluted earnings per share
85.82%-5.28
-9.63%-37.23
25.93%-33.96
-45.8515
Dividend per share
Currency Unit
AUD
AUD
AUD
AUD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
(FY)Jun 30, 2025(FY)Jun 30, 2024(FY)Jun 30, 2023(FY)Jun 30, 2022
Total revenue 1,114.27%3.63M2.35%299.23K3,210.60%292.36K8.83K
Operating revenue 1,114.27%3.63M2.35%299.23K3,210.60%292.36K--8.83K
Cost of revenue 3.59M00
Gross profit -86.87%39.28K2.35%299.23K3,210.60%292.36K8.83K
Operating expense -7.45%34.68M17.17%37.47M60.52%31.98M19.93M
Selling and administrative expenses 5.45%16.53M2.68%15.67M36.12%15.26M--11.21M
-General and administrative expense 5.45%16.53M2.68%15.67M36.12%15.26M--11.21M
Research and development costs 19.18%27.52M2.01%23.09M448.68%22.63M--4.12M
Depreciation amortization depletion -2.69%7.33K14.97%7.53K-99.78%6.55K--2.98M
-Depreciation and amortization -2.69%7.33K14.97%7.53K-99.78%6.55K--2.98M
Other operating expenses -624.80%-9.37M78.16%-1.29M-468.28%-5.92M--1.61M
Operating profit 6.81%-34.64M-17.30%-37.17M-59.12%-31.69M-19.92M
Net non-operating interest income expense 247.60%333.11K-482.88%-225.69K100.63%58.94K-9.35M
Non-operating interest income 1,659.36%888.2K-65.19%50.48K--145.04K----
Non-operating interest expense -89.84%65.3K646.75%642.89K-99.08%86.09K--9.35M
Total other finance cost 233.56%489.79K---366.72K--------
Other net income (expense) 62.39%-3.93M-255.37%-10.45M-186.00%-2.94M-1.03M
Gain on sale of security 45.47%138.14K136.91%94.96K74.99%-257.25K---1.03M
Special income (charges) 61.42%-4.07M-292.96%-10.55M---2.68M----
-Less:Restructuring and merger&acquisition -54.07%4.07M230.08%8.86M--2.68M----
-Less:Impairment of capital assets -----52.29%1.48M--3.1M----
-Gain on sale of property,plant,equipment --0---1.69M--0----
Other non- operating income (expenses) -----227.89%-7.57M--5.92M----
Income before tax 20.09%-38.24M-38.41%-47.85M-14.12%-34.57M-30.29M
Income tax 7.19%103.29K153.56%96.36K-14.40%38.01K44.4K
Net income 20.04%-38.34M-38.54%-47.95M-14.08%-34.61M-30.34M
Net income continuous Operations 20.04%-38.34M-38.54%-47.95M-14.08%-34.61M---30.34M
Minority interest income
Net income attributable to the parent company 20.04%-38.34M-38.54%-47.95M-14.08%-34.61M-30.34M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 20.04%-38.34M-38.54%-47.95M-14.08%-34.61M-30.34M
Basic earnings per share 85.82%-5.28-9.63%-37.2325.93%-33.96-45.8515
Diluted earnings per share 85.82%-5.28-9.63%-37.2325.93%-33.96-45.8515
Dividend per share
Currency Unit AUDAUDAUDAUD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion------
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On the morning of the 11th, Eastern Time, Trump stated he would launch a military strike against Iran that evening, targeting core oil facil Show More